Initially, GBM expression of IDO1 was thought to positively correlate with tumor grade mediated by the metabolic effects of IDO1; however, recent work has also uncovered non-metabolic IDO1-driven pro-tumoral effects. This evidence concerns the gene IDO1 and glioblastoma.